.webp)
67/100B67.290
USD
-0.26
(-0.38%)
Post Trading·68.800USD+1.510(+2.24%)
Last updated: · Delayed 15 min
Fair value63.11Plus+7%48Price 67.2994
Q4 FY2026 · Earnings report
EPS estimate 1.53Revenue estimate 960.74M
Q4 FY2026 · Earnings report
EPS estimate 1.53Revenue estimate 960.74M
If you had invested in Royalty Pharma ago, it would be worth $1,909 today, against $2,277 in SPY and $2,307 in QQQ.
Arincen ScoreWhat is the Arincen Score? The Arincen Score grades a company out of 100 from 30 checks on its own reported figures, five checks in each of six parts.Beta
67/100
Six parts of the company, five checks each, from its own reported figures. A part scores the checks it passes out of 10; the score is their average out of 100.
Profitability8
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Cash10
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Valuation6
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Growth8
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Financial strength2
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Shareholders6
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Figures to FY2025; the price as of today.
Royalty Pharma key facts
- StyleWhat does a stock's style mean? The style label sorts a stock as growth, value, dividend, blend or speculative, with a 1 to 10 meter showing how strongly it fits.
- Blend stock · 5.1/10Growth 3.6 · Value 5.1 · Dividend 3.8
- Day range
- 66.760 – 68.120
- 52-week range
- 37.310 – 69.770
- Market capitalizationWhat is market capitalization? Market cap is what the stock market values a whole company at: its share price times the number of its shares outstanding.
- 29.96B USD
- P/EWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 39.81
- PEG ratioWhat is the PEG ratio? The PEG ratio divides the P/E by the yearly earnings growth analysts expect, to show how much you pay for each point of growth.
- 0.49
- EPSWhat is EPS (earnings per share)? EPS (earnings per share) is a company's net income divided by its number of shares: the profit that belongs to each share over a period.
- 1.69
- Div YieldWhat is dividend yield? Dividend yield is a year of dividends as a percentage of the share price: the income a shareholder receives for each dollar invested at today's price.
- 1.40%
- EPS growth forecast (FY2026)
- +11.6%
- Volume
- 1
- BetaWhat is beta in stocks? Beta measures how much a stock tends to move when the whole market moves: 1 moves with it, under 1 is calmer, over 1 swings more.
- 0.41
- ESG scoreWhat is an ESG score? An ESG score rates how a company handles the environment, its people and its governance, out of 100. Higher is better.
- 65.7/100Environment 63 · Social 66 · Governance 68
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Pablo Legorreta
- Employees
- 100
- Website
- royaltypharma.com
- IPO date
- 16 Jun 2020
Royalty Pharma earningsWhat is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
Next earnings · Q4 FY2026
EPS estimate
1.53 USD
Revenue estimate
960.74M USD
Last quarter · Q3 FY2026
EPS1.21Beat +2.5%Revenue890.00MBeat +0.6%
Revenue
ReportedEstimate
EPS
ReportedEstimate
| Period | Report date | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|---|
| Q4 FY2026 | 1.53 | — | — | +4.79% | 960.74M | — | — | +9.92% | |
| Q3 FY2026 | 1.18 | 1.21 | +2.54% | +3.42% | 884.84M | 890.00M | +0.58% | +46.07% | |
| Q2 FY2026 | 1.27 | 1.32 | +3.94% | +15.79% | 758.93M | 773.00M | +1.85% | +33.58% | |
| Q1 FY2026 | 1.21 | 1.30 | +7.44% | +22.64% | 881.69M | 925.00M | +4.91% | +62.78% | |
| Q4 FY2025 | 1.29 | 1.46 | +13.18% | +26.96% | 806.96M | 874.00M | +8.31% | +47.14% | |
| Q3 FY2025 | 0.99 | 1.17 | +17.71% | +12.50% | 717.38M | 609.29M | -15.07% | +7.90% | |
| Q2 FY2025 | 1.03 | 1.14 | +10.68% | +18.75% | 672.99M | 578.67M | -14.02% | +7.71% |
| Period | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|
| FY2027 | 5.91 | — | — | +9.61% | 3.86B | — | — | +9.09% |
| FY2026 | 5.39 | — | — | +11.65% | 3.54B | — | — | +34.57% |
| FY2025 | 4.63 | 4.83 | +4.25% | +16.95% | 3.01B | 2.63B | -12.59% | +16.18% |
| FY2024 | 4.05 | 4.13 | +2.00% | -5.92% | 2.69B | 2.26B | -15.79% | -3.85% |
| FY2023 | 4.24 | 4.39 | +3.66% | +18.97% | 2.99B | 2.35B | -21.15% | +5.24% |
| FY2022 | 3.64 | 3.69 | +1.48% | +26.80% | 2.79B | 2.24B | -19.85% | -2.28% |
Royalty Pharma analyst forecastWhat is the analyst rating? The analyst rating sums up what the analysts covering a stock recommend, from strong buy to strong sell, by the share of them rating it a buy.
12-month price target
66.50 USD
-1.17%
Analysts' 1-year price targets range from 66.00 to 67.00, with an average of 66.50.
Past year
1-year forecast
Strong sellStrong buy
Strong buy
5 ratings
| Buy | 5 | |
| Hold | 0 | |
| Sell | 0 |
12-month price target
| Highest target | 67.00 |
| Average target | 66.50 |
| Lowest target | 66.00 |
| Current price | 67.29 |
Royalty Pharma valuationWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- Price to earnings ratio (TTM)What is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 39.81
- Forward P/E (FY2026)What is the forward P/E ratio? Forward P/E divides a share's price by the earnings per share analysts expect in the coming year, rather than last year's actual earnings.
- 12.48
- Price to sales (TTM)What is the P/S ratio? The price-to-sales ratio compares a company's market value with its revenue over the last year: what you pay for each dollar of sales.
- 11.45
- Price to bookWhat is the P/B ratio? The price-to-book ratio compares a company's market value with its book value, the shareholders' equity on its balance sheet.
- 4.38
Capital structureWhat is enterprise value? Enterprise value is what the whole business costs: the market value of its shares plus its debt minus its cash. It is the price behind EV/EBITDA.
Market capitalization
29.96B USD
+
Total debt
8.59B USD
−
Cash and short-term investments
544.86M USD
=
Enterprise value
38.00B USD
Valuation over time
P/EForward P/EForward P/E · EstimateEstimate
Royalty Pharma against its own historyWhat does "against its own history" show? The company's latest margins, return on equity, growth, debt and P/E against its own last 5 years: the low, the median and the high, and whether this year is better or worse than usual.
Each figure in the latest fiscal year against the same figure from FY2021 to FY2025: the range, its median (the line) and the latest (the dot, green on the good side of the median). The P/E is today's against its daily readings of five years.
Its peers: Labcorp Holdings, Illumina, DexCom, Quest Diagnostics, West Pharmaceutical Services, and Mettler-Toledo International, the US Healthcare companies closest to it in size, each in its own latest fiscal year: their median (the line) and its rank among them, first being the best.
- P/E (today)Above its median39.88.23,021.0
- Gross marginAt its median100.0%100.0%100.0%Against its peers: 1 of 7Peers' median 47.6%
- Operating marginHighest in 5 years65.6%13.7%65.6%Against its peers: 1 of 7Peers' median 19.7%
- Net marginAt its median32.4%1.9%48.2%Against its peers: 1 of 7Peers' median 17.0%
- Return on equityAt its median11.9%0.8%17.4%Against its peers: 5 of 6Peers' median 15.5%
- Free cash flow marginAt its median104.7%88.1%126.9%Against its peers: 1 of 7Peers' median 18.2%
- Revenue growthAt its median5.1%-3.9%7.9%Against its peers: 5 of 7Peers' median 6.8%
- EPS growthAt its median-5.8%-93.3%2,430.0%Against its peers: 6 of 6Peers' median 13.8%
- Debt to EBITDAAbove its median5.47×3.25×16.80×Against its peers: 7 of 7Peers' median 1.82×
- Current ratioLowest in 5 years0.970.9716.81Against its peers: 7 of 7Peers' median 1.65
Peers: US companies of the same industry (of its sector when the industry has too few) from a tenth to ten times its market value, the six closest in size. Updated weekly.
Royalty Pharma growth and profitabilityWhat are gross, operating and net profit margins? A profit margin is the share of revenue kept as profit: gross margin after the cost of sales, operating margin after running costs, net margin after all costs.
- Revenue (TTM)What does TTM (trailing twelve months) mean? TTM (trailing twelve months) is a figure over the latest twelve months of reports: usually the last four quarters added together.
- 2.62B USD
- Net income (TTM)What is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.
- 672.09M USD
- Net margin
- 25.68%
Revenue / Net income
Revenue Net income Net margin
Royalty Pharma revenue breakdown
By product
FY2025
95.1%Financial Royalty Assets4.9%Royalty Income, Other
| Segment | Revenue | Share of revenue | Change on the year |
|---|---|---|---|
| Financial Royalty Assets | 2.26B | 95.1% | +5.2% |
| Royalty Income, Other | 117.04M | 4.9% | +2.5% |
How Royalty Pharma makes its moneyWhat is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.
Financial Royalty Assets2.26B 95.1%
Royalty Income, Other117.04M 4.9%
Revenue2.38B 100.0%
Gross profit2.38B 100.0%
Research and development452.00M 19.0%
Selling and administration573.48M 24.1%
Operating income1.56B 65.6%
Other expense788.57M 33.2%
Net income770.95M 32.4%
FY2025, in USD. Each band is as wide as its money; the percentage is its share of revenue.
FY2025, in USD. Each band is as wide as its money; the percentage is its share of revenue.
Royalty Pharma dividendsWhat is dividend yield? Dividend yield is a year of dividends as a percentage of the share price: the income a shareholder receives for each dollar invested at today's price.
- Annual dividend
- 0.94 USD
- Dividend yield (indicated)What is dividend yield? Dividend yield is a year of dividends as a percentage of the share price: the income a shareholder receives for each dollar invested at today's price.
- 1.40%
- Payout ratioWhat is the payout ratio? The payout ratio is the share of a company's earnings paid out as dividends: dividends per share divided by earnings per share (EPS).
- 68.62%
- Years of dividend growthWhat are years of dividend growth? The years in a row a company has raised its dividend per share. 25 years make an S&P 500 company a Dividend Aristocrat; 50 make a Dividend King.
- 6
- Frequency
- Quarterly
- Next payment
- 0.24 USD
- Next ex-dividend dateWhat is the ex-dividend date? The ex-dividend date is the first day a stock trades without its next dividend: buy before it to receive the payment; buy on or after it and the seller gets it.
- 13 Nov 2026
- Next payment date
- 10 Dec 2026
Dividends per share
Royalty Pharma financial health
- Cash and short-term investments
- 544.86M USD
- Total debt
- 8.59B USD
- Net cash
- -8.04B USD
- Free cash flow (TTM)What is free cash flow (FCF)? Free cash flow is the cash a company's operations bring in minus what it spends on long-term assets (capex): cash left for debt, dividends and buybacks.
- 2.96B USD
- Current ratioWhat is the current ratio? The current ratio is current assets divided by current liabilities: whether what a company will turn into cash within a year covers what it owes within a year.
- 1.29
- Debt to equityWhat is the debt to equity ratio? Debt to equity is a company's total debt divided by its shareholders' equity: how much it has borrowed for each dollar its owners have in the business.
- 1.26
- Piotroski scoreWhat is the Piotroski F-Score? The Piotroski F-Score rates a company's financial strength from 0 to 9: one point for each of nine tests of profit, debt and efficiency it passes.
- 6 / 9
- Altman Z-scoreWhat is the Altman Z-Score? The Altman Z-Score rolls five financial ratios into one number that signals a company's risk of bankruptcy: over 3 is safe, under 1.8 is distress.
- 2.47
Cash, debt and free cash flow
Cash and short-term investments Total debt Free cash flow
Royalty Pharma ownershipWhat is institutional ownership? Institutional ownership is the share of a company's stock held by funds, banks and other investment managers, as they report it each quarter on Form 13F.
- InstitutionsWhat is institutional ownership? Institutional ownership is the share of a company's stock held by funds, banks and other investment managers, as they report it each quarter on Form 13F.
- 83.18%
- Institutional holders
- 660 (+57)
- Free floatWhat is free float? Free float is the part of a company's shares that anyone can buy and sell: all its shares minus those held by insiders, founders and owners of over 5%.
- 93.97%
Who owns the shares
Institutions 83.2% Others 16.8%
As of 30 Jun 2026
Shares free to trade
Free float 418.41M shares ·94.0% Closely held 26.86M shares ·6.0%
Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.
Insider trading
| Quarter | Purchases | Sales | Shares acquired | Shares disposed of |
|---|---|---|---|---|
| Q4 2026 | 0 | 1 | 0.00 | 4.13K |
| Q3 2026 | 0 | 7 | 96.11K | 292.53K |
| Q2 2026 | 0 | 11 | 247.59K | 323.49K |
| Q1 2026 | 0 | 23 | 231.87K | 587.08K |
Shares outstanding
Basic shares Diluted shares Change in diluted shares
Source: Financial Modeling Prep
Title: Royalty Pharma plc
Sector: Healthcare
Industry: Medical - Pharmaceuticals
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.